Rocio Talaveron
Sevilla, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
The Src inhibitor peptide TAT-Cx43266-283 improves survival in an intracranial murine model of lung cancer brain metastasis.
Journal: Neuro-oncology advances
Published: November 24, 2025
The Gap Junction Inhibitor Octanol Decreases Proliferation and Increases Glial Differentiation of Postnatal Neural Progenitor Cells.
Journal: International journal of molecular sciences
Published: March 30, 2024
A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma.
Journal: Translational research : the journal of laboratory and clinical medicine
Published: March 12, 2024
Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth.
Journal: Cancer letters
Published: October 26, 2023
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma.
Journal: Journal of visualized experiments : JoVE
Published: June 19, 2023
Antiproliferative effect of boldine on neural progenitor cells and on glioblastoma cells.
Journal: Frontiers in neuroscience
Published: April 24, 2023
Purinergic Receptor Blockade with Suramin Increases Survival of Postnatal Neural Progenitor Cells In Vitro.
Journal: International journal of molecular sciences
Published: December 17, 2020
Connexin43 Region 266-283, via Src Inhibition, Reduces Neural Progenitor Cell Proliferation Promoted by EGF and FGF-2 and Increases Astrocytic Differentiation.
Journal: International journal of molecular sciences
Published: November 04, 2020
Erratum to 'Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo'.
Journal: Neuro-oncology
Published: June 10, 2020
Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283.
Journal: EBioMedicine
Published: March 05, 2020
Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo.
Journal: Neuro-oncology
Published: December 29, 2019
Last Updated: 09/26/2026